DiviTum® TKa is a blood-based biomarker test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer. The DiviTum TKa blood test measures thymidine kinase activity (TKa) which reflects cell proliferation.

 

 

Clinical Evidence
About The Test

Biovica is a Swedish biotech company founded in 2009, committed to developing and commercializing novel blood-based biomarker assays. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.

About Biovica

Next-level mBC Monitoring

DiviTum® TKa is an innovative tumor TK activity (TKa) profile test for early prognosis and prediction of metastatic breast cancer treatment outcomes in postmenopausal HR+ mBC patients.1-4

References:

1. Bergqvist M, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. Vol 28, 2023: 313-322.

2. Paoletti C, et al. Evaluating serum thymidine kinase 1 in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial. Clin Cancer Res. 2021;27(22):6115-6123.

3. Malorni L, et al. International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.

4. Malorni L, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11. Eur J Cancer 2023; 186: 1–11.

TKa as a Biomarker

Learn more about what makes TKa an important oncology biomarker.

The Science Behind TKa
Anders
I am certain that the DiviTum TKa test will improve the care for many cancer patients.
Anders Rylander
CEO - Biovica

PLEASE SELECT ONE

Please specify your home location

USA
Europe/Rest of World